|
Galvus®, a new oral treatment for type 2 diabetes, receives positive opinion
|
20 December 2007 |
|
Novartis further strengthens biologics capabilities in expansion of MorphoSys collaboration
|
05 December 2007 |
|
Novartis withdraws its application to extend the marketing authorisation for Zometa
|
21 November 2007 |
|
Menveo(TM) (MenACWY-CRM) vaccine to demonstrate an excellent immune response in infants
|
19 November 2007 |
|
Tasigna® receives US approval providing new hope to chronic myeloid leukemia patients
|
02 November 2007 |
|
Novartis delivers record earnings in first nine months of 2007
|
20 October 2007 |
|
Aclasta® receives European approval as first once-yearly treatment for postmenopausal osteoporosis
|
08 October 2007 |
|
Novartis and Massachusetts Institute of Technology (MIT) in new partnership
|
01 October 2007 |
|
Tasigna® recommended for European approval to treat rare form of leukemia
|
24 September 2007 |
|
Novartis completes agreement with Bayer Schering related to Betaseron®
|
15 September 2007 |